Background

Data on composite and sequential lymphoma between primary mediastinal lymphoma/diffuse large B-cell lymphoma (LBCL) and classical Hodgkin lymphoma (cHL) are rare.

Methods

We identified 25 cases with composite lymphoma (CL), 116 cases developing LBCL as a second primary cancer after cHL (cHL-LBCL), and 74 cases developing cHL as a second primary cancer after LBCL (LBCL-cHL) from the Surveillance, Epidemiology, and End Results (SEER) 18 database. Comparisons of overall survival (OS) and lymphoma cause-specific survival (CSS) between patients with cHL-LBCL or cHL-LBCL and their de novo counterparts were performed.

Results

The 5-year OS of patients with CL was 74.8 %. No significant difference in unadjusted OS and lymphoma CSS were observed between patients with de novo LBCL (LBCL-1 group) and patients with cHL-LBCL. However, the age- and stage-adjusted cHL-LBCL group had inferior OS and lymphoma CSS compared with that in the LBCL-1 group. The unadjusted and adjusted OS and lymphoma CSS in the LBCL-cHL group were significantly worse than patients with de novo cHL.

Conclusions

CL between LBCL and cHL may have good outcomes. cHL survivors had poorer outcomes after a LBCL diagnosis versus patients with LBCL-1. Significantly poor outcomes were observed in patients with LBCL-cHL compared with patients with de novo cHL.

中文翻译：

---

原发性纵隔淋巴瘤/弥漫性大 B 细胞淋巴瘤和经典霍奇金淋巴瘤之间的复合和序贯淋巴瘤患者的生存率：基于人群的研究

背景

原发性纵隔淋巴瘤/弥漫性大 B 细胞淋巴瘤 (LBCL) 和经典霍奇金淋巴瘤 (cHL) 之间的复合和序贯淋巴瘤的数据很少。

方法

我们确定了 25 例复合淋巴瘤 (CL)，116 例将 LBCL 发展为继 cHL (cHL-LBCL) 之后的第二原发癌，以及 74 例将 cHL 发展为继 LBCL (LBCL-cHL) 之后的第二原发癌症。和最终结果 (SEER) 18 数据库。比较了 cHL-LBCL 或 cHL-LBCL 患者及其新发患者的总生存期 (OS) 和淋巴瘤病因特异性生存期 (CSS)。

结果

CL 患者的 5 年 OS 为 74.8%。在新发 LBCL 患者（LBCL-1 组）和 cHL-LBCL 患者之间未观察到未经调整的 OS 和淋巴瘤 CSS 没有显着差异。然而，与 LBCL-1 组相比，经过年龄和阶段调整的 cHL-LBCL 组的 OS 和淋巴瘤 CSS 较差。LBCL-cHL 组未调整和调整后的 OS 和淋巴瘤 CSS 明显低于新发 cHL 患者。

结论

LBCL 和 cHL 之间的 CL 可能有良好的结果。与 LBCL-1 患者相比，确诊 LBCL 后 cHL 幸存者的预后较差。与新发 cHL 患者相比，LBCL-cHL 患者的预后明显较差。